Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Scribe Therapeutics
Biotech
Scribe notes IPO plan to push lipid-lowering meds through clinic
Scribe is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.
James Waldron
Jul 6, 2026 7:54am
Scribe eyes clinic as CRISPR candidates lower lipids in animals
Nov 17, 2025 9:22am
Gene editor Scribe slims down workforce as it readies for clinic
Jan 8, 2025 5:33pm
Sanofi, Scribe seal new in vivo collab worth more than $1.2B
Jul 17, 2023 11:30am
Scribe's CRISPR tech Prevails with new $1.5B Lilly biobucks deal
May 16, 2023 9:00am
Sanofi pays Scribe $25M for CRISPR NK cell therapy project
Sep 27, 2022 8:15am
